Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
targetedmolecules.com

See what CB Insights has to offer

Total Raised

$16.3M

Investors Count

8

Deal Terms

3

Targeted Molecules Funding, Targeted Molecules Valuation & Targeted Molecules Revenue

4 Fundings

Targeted Molecules's latest funding round was a Acquired for on February 23, 2006.

Targeted Molecules's valuation in April 2001 was $15.13M.

Targeted Molecules's latest post-money valuation is from February 2006.

Sign up for a free 30-day trial to see Targeted Molecules's valuations in February 2006 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/23/2006

Acquired

$99M

$0.00B

((9.99x))

FY 1234

9/19/2003

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

12/17/2001

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

4/1/2001

Series A

$99M

$15.13M

$0.00B

((9.99x))

FY 1234

10

Date

2/23/2006

9/19/2003

12/17/2001

4/1/2001

Round

Acquired

Series C

Series B

Series A

Amount

$99M

$99M

$99M

Investors

Valuation

$99M

$15.13M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

10

10

10

Targeted Molecules Deal Terms

3 Deal Terms

Targeted Molecules's deal structure is available for 3 funding rounds, including their Acquired from February 23, 2006.

Round

Acquired

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

Targeted Molecules Investors

8 Investors

Targeted Molecules has 8 investors. Calyx Bio-Ventures invested in Targeted Molecules's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/23/2006

2/23/2006

1
Acquired

Corporation

Canada

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Private Equity

Canada

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

First funding

2/23/2006

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

2/23/2006

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Corporation

Private Equity

Venture Capital

Location

Canada

Canada

California

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.